Synergy CHC Corp. (Uplisting) (SNYR) Competitors $3.21 -0.10 (-3.02%) As of 03/27/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SNYR vs. SLN, IMUX, GALT, ANIX, KYTX, BMEA, BDTX, JAGX, PLRX, and VTYXShould you be buying Synergy CHC Corp. (Uplisting) stock or one of its competitors? The main competitors of Synergy CHC Corp. (Uplisting) include Silence Therapeutics (SLN), Immunic (IMUX), Galectin Therapeutics (GALT), Anixa Biosciences (ANIX), Kyverna Therapeutics (KYTX), Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Jaguar Health (JAGX), Pliant Therapeutics (PLRX), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry. Synergy CHC Corp. (Uplisting) vs. Silence Therapeutics Immunic Galectin Therapeutics Anixa Biosciences Kyverna Therapeutics Biomea Fusion Black Diamond Therapeutics Jaguar Health Pliant Therapeutics Ventyx Biosciences Silence Therapeutics (NASDAQ:SLN) and Synergy CHC Corp. (Uplisting) (NASDAQ:SNYR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends. Do institutionals and insiders hold more shares of SLN or SNYR? 98.7% of Silence Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, SLN or SNYR? Synergy CHC Corp. (Uplisting) has lower revenue, but higher earnings than Silence Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics$43.26M2.55-$53.82M-$0.95-3.88Synergy CHC Corp. (Uplisting)$26.01M1.07N/AN/AN/A Is SLN or SNYR more profitable? Synergy CHC Corp. (Uplisting) has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Synergy CHC Corp. (Uplisting)'s return on equity of 0.00% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silence Therapeutics-342.00% -62.81% -33.89% Synergy CHC Corp. (Uplisting) N/A N/A N/A Does the MarketBeat Community believe in SLN or SNYR? Silence Therapeutics received 41 more outperform votes than Synergy CHC Corp. (Uplisting) when rated by MarketBeat users. Likewise, 79.63% of users gave Silence Therapeutics an outperform vote while only 66.67% of users gave Synergy CHC Corp. (Uplisting) an outperform vote. CompanyUnderperformOutperformSilence TherapeuticsOutperform Votes4379.63% Underperform Votes1120.37% Synergy CHC Corp. (Uplisting)Outperform Votes266.67% Underperform Votes133.33% Do analysts recommend SLN or SNYR? Silence Therapeutics presently has a consensus target price of $40.67, suggesting a potential upside of 1,002.08%. Synergy CHC Corp. (Uplisting) has a consensus target price of $10.00, suggesting a potential upside of 211.53%. Given Silence Therapeutics' higher possible upside, research analysts clearly believe Silence Therapeutics is more favorable than Synergy CHC Corp. (Uplisting).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Synergy CHC Corp. (Uplisting) 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media refer more to SLN or SNYR? In the previous week, Silence Therapeutics and Silence Therapeutics both had 2 articles in the media. Silence Therapeutics' average media sentiment score of 1.61 beat Synergy CHC Corp. (Uplisting)'s score of 0.94 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Synergy CHC Corp. (Uplisting) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySilence Therapeutics beats Synergy CHC Corp. (Uplisting) on 9 of the 14 factors compared between the two stocks. Remove Ads Get Synergy CHC Corp. (Uplisting) News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHC Corp. (Uplisting)Medicinals & botanicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$27.94M$1.12B$16.91B$8.06BDividend YieldN/AN/A2.89%4.02%P/E RatioN/A9.6816.5619.03Price / Sales1.076.242.6893.17Price / CashN/A10.4016.3934.64Price / BookN/A1.236.814.33Net IncomeN/A-$53.09M$734.56M$247.06M7 Day Performance2.88%-4.03%0.39%-0.53%1 Month Performance-15.53%-15.89%5.32%-3.74%1 Year PerformanceN/A-41.94%3.12%1.72% Synergy CHC Corp. (Uplisting) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC Corp. (Uplisting)3.6495 of 5 stars$3.21-3.0%$10.00+211.5%N/A$27.94M$26.01M0.0040Gap DownSLNSilence Therapeutics2.2141 of 5 stars$3.49-2.0%$40.67+1,065.2%-83.1%$104.46M$43.26M-2.22100Positive NewsIMUXImmunic2.6275 of 5 stars$1.17+1.7%$12.67+982.6%-4.6%$103.59MN/A-0.9570Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageGALTGalectin Therapeutics1.6989 of 5 stars$1.65+3.8%$11.00+566.7%-30.3%$103.56MN/A-2.269News CoverageGap UpANIXAnixa Biosciences3.1823 of 5 stars$3.20+1.3%$9.00+181.3%-4.6%$103.03M$210,000.00-8.215Analyst ForecastAnalyst RevisionNews CoverageGap UpKYTXKyverna Therapeutics1.4584 of 5 stars$2.35-1.3%$18.40+683.0%-90.2%$102.75M$7.03M0.0096Earnings ReportNews CoverageGap UpBMEABiomea Fusion3.1304 of 5 stars$2.79-2.8%$29.18+945.9%-83.8%$101.11MN/A-0.7050BDTXBlack Diamond Therapeutics3.236 of 5 stars$1.68-5.6%$14.60+769.0%-65.9%$100.86MN/A-1.2690High Trading VolumeJAGXJaguar Health0.5858 of 5 stars$6.04+4.6%N/A-95.1%$99.07M$10.48M0.0050Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumePLRXPliant Therapeutics4.3309 of 5 stars$1.59+2.6%$13.31+737.3%-89.6%$97.37M$1.58M-0.4890Short Interest ↑VTYXVentyx Biosciences2.4758 of 5 stars$1.36+3.0%$10.00+635.3%-78.8%$96.74MN/A-0.5830Positive News Remove Ads Related Companies and Tools Related Companies Silence Therapeutics Competitors Immunic Competitors Galectin Therapeutics Competitors Anixa Biosciences Competitors Kyverna Therapeutics Competitors Biomea Fusion Competitors Black Diamond Therapeutics Competitors Jaguar Health Competitors Pliant Therapeutics Competitors Ventyx Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. (Uplisting) Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC Corp. (Uplisting) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
